Journey Medical (DERM) Receivables (2020 - 2026)

Journey Medical has reported Receivables for 7 years, with the latest figure at $25.0 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 38.65% year-over-year to $25.0 million; the trailing twelve-month figure through Mar 2026 stood at $25.0 million (up 38.65% YoY), and the FY2025 full-year result was $29.8 million, up 191.11% from the prior year.
• Receivables for Q1 2026 stood at $25.0 million, down from $29.8 million in the prior quarter.
• The five-year high for Receivables was $31.2 million in Q1 2022, with the low at $8.0 million in Q3 2023.
• Historically, Receivables has averaged $19.5 million across 5 years, with a median of $18.0 million in 2025.
• Annual changes were most pronounced in 2023 — Receivables plunged 72.0% — and 2025, when it surged 191.11%.
• Journey Medical's Receivables stood at $28.2 million in 2022, then tumbled by 46.04% to $15.2 million in 2023, then tumbled by 32.79% to $10.2 million in 2024, then surged by 191.11% to $29.8 million in 2025, then decreased by 16.09% to $25.0 million in 2026.
• The last three Receivables figures came in at $25.0 million (Q1 2026), $29.8 million (Q4 2025), and $18.0 million (Q3 2025), per Business Quant data.